Literature DB >> 23839107

Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore.

Anke Harenberg1, Sarah Begue, Audrey Mamessier, Sophie Gimenez-Fourage, Ching Ching Seah, Ai Wei Liang, Jun Li Ng, Xue Yun Toh, Sophia Archuleta, Annelies Wilder-Smith, Lynette P Shek, Anh Wartel-Tram, Alain Bouckenooghe, Jean Lang, Denis Crevat, Catherine Caillet, Bruno Guy.   

Abstract

To characterize the cell mediated immunity (CMI) induced by the investigational CYD tetravalent dengue vaccine (TDV), we developed a whole-blood, intracellular cytokine staining (ICS) assay and a multiplex assay, each requiring 3 mL of blood. We assessed CMI before and 28 d after a first and third injection of CYD-TDV and one year after the third injection in a subset of 80 adolescents and adults enrolled in a phase II trial in Singapore (ClinicalTrial.gov NCT NCT00880893). CD4/IFNγ/TNFα responses specific to dengue NS3 were detected before vaccination. Vaccination induced YF-17D-NS3-specific CD8/IFNγ responses, without significant TNFα, and a CYD-specific Th1/Tc1 cellular response in all participants, which was characterized by predominant IFNγ secretion compared with TNFα, associated with low level IL-13 secretion in multiplex analysis of peripheral blood mononuclear cells (PBMC) supernatants after restimulation with each the CYD vaccine viruses. Responses were directed mainly against CYD-4 after the first vaccination, and were more balanced against all four serotypes after the third vaccination. The same qualitative profile was observed one year after the third vaccination, with approximately 2-fold lower NS3-specific responses, and 3-fold lower serotype-specific cellular responses. These findings confirm previous observations regarding both the nature and specificity of cellular responses induced by CYD-TDV, and for the first time demonstrate the persistence of cellular responses after one year. We also established the feasibility of analyzing CMI with small blood samples, allowing such analysis to be considered for pediatric trials.

Entities:  

Keywords:  cell mediated immunity; cytokines; intracellular cytokine staining; tetravalent dengue vaccine; whole blood

Mesh:

Substances:

Year:  2013        PMID: 23839107      PMCID: PMC3981840          DOI: 10.4161/hv.25562

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  29 in total

1.  Critical parameters in blood processing for T-cell assays: validation on ELISpot and tetramer platforms.

Authors:  Georgia Afonso; Matthieu Scotto; Amédée Renand; Jeanette Arvastsson; Dominique Vassilieff; Corrado M Cilio; Roberto Mallone
Journal:  J Immunol Methods       Date:  2010-07-31       Impact factor: 2.303

Review 2.  Immunopathological mechanisms in dengue and dengue hemorrhagic fever.

Authors:  Sharone Green; Alan Rothman
Journal:  Curr Opin Infect Dis       Date:  2006-10       Impact factor: 4.915

Review 3.  Prospects for a dengue virus vaccine.

Authors:  Stephen S Whitehead; Joseph E Blaney; Anna P Durbin; Brian R Murphy
Journal:  Nat Rev Microbiol       Date:  2007-07       Impact factor: 60.633

Review 4.  Towards a dengue vaccine: progress to date and remaining challenges.

Authors:  Bruno Guy; Jeffrey W Almond
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2007-09-21       Impact factor: 2.268

Review 5.  Dengue vaccine candidates in development.

Authors:  Anna P Durbin; Stephen S Whitehead
Journal:  Curr Top Microbiol Immunol       Date:  2010       Impact factor: 4.291

Review 6.  From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Authors:  Bruno Guy; Beatrice Barrere; Claire Malinowski; Melanie Saville; Remy Teyssou; Jean Lang
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

7.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

8.  Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok.

Authors:  B Adams; E C Holmes; C Zhang; M P Mammen; S Nimmannitya; S Kalayanarooj; M Boots
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

Review 9.  Interleukin-4 and interleukin-13: their similarities and discrepancies.

Authors:  P Chomarat; J Banchereau
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

10.  Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.

Authors:  Yee Sin Leo; Anneliese Wilder-Smith; Sophia Archuleta; Lynette P Shek; Chia-Yin Chong; Hoe Nam Leong; Chian Yong Low; May-Lin Helen Oh; Alain Bouckenooghe; T Anh Wartel; Denis Crevat
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

View more
  29 in total

Review 1.  Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections.

Authors:  Anuja Mathew; Elizabeth Townsley; Francis A Ennis
Journal:  Future Microbiol       Date:  2014       Impact factor: 3.165

Review 2.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.

Authors:  Bruno Guy
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 3.  Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  Curr Opin Immunol       Date:  2019-03-15       Impact factor: 7.486

4.  Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.

Authors:  Peter B Gilbert; Ying Huang; Michal Juraska; Zoe Moodie; Youyi Fong; Alexander Luedtke; Yingying Zhuang; Jason Shao; Lindsay N Carpp; Nicholas Jackson; Laurent Chambonneau; Alain Bouckenooghe; Betzana Zambrano; Carina Frago; Sophie Pallardy; Fernando Noriega
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

5.  Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.

Authors:  Zoe Moodie; Michal Juraska; Ying Huang; Yingying Zhuang; Youyi Fong; Lindsay N Carpp; Steven G Self; Laurent Chambonneau; Robert Small; Nicholas Jackson; Fernando Noriega; Peter B Gilbert
Journal:  J Infect Dis       Date:  2018-02-14       Impact factor: 5.226

Review 6.  CD4+ and CD8+ T-cell immunity to Dengue - lessons for the study of Zika virus.

Authors:  Laura Rivino; Mei Qiu Lim
Journal:  Immunology       Date:  2016-11-27       Impact factor: 7.397

Review 7.  Recent progress in dengue vaccine development.

Authors:  Jianchun Wei; Hui Chen; Jing An
Journal:  Virol Sin       Date:  2014-12-24       Impact factor: 4.327

Review 8.  Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-09       Impact factor: 9.546

Review 9.  Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.

Authors:  Bruno Guy; Nicholas Jackson
Journal:  Nat Rev Microbiol       Date:  2015-12-07       Impact factor: 60.633

10.  Immunopathogenesis Versus Protection in Dengue Virus Infections.

Authors:  Alan L Rothman; Carey L Medin; Heather Friberg; Jeffrey R Currier
Journal:  Curr Trop Med Rep       Date:  2014-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.